Why the study?
Does aspirin reduce recurrent myocardial infarction and death in patients with MI or unstable angina?
Does aspirin reduce recurrent myocardial infarction and death in patients with MI or unstable angina?
Aspirin 325 mg daily is an effective and well-tolerated therapy for the secondary prevention of recurrent MI and death in patients with a history of MI or unstable angina.
Answers are grounded in this paper and cite their sources.
Supports aspirin 325 mg daily for secondary prevention post-MI; leaves open need for updated RCTs in contemporary populations.
In October 1985, the Food and Drug Administration approved a new indication of aspirin for the secondary prevention of recurrent myocardial infarction (MI) and death in patients with MI or unstable angina. Clinical trials have demonstrated the efficacy of this drug, especially when treatment is begun soon after the initial event. The antiplatelet actions of aspirin seem to be the most plausible explanation for its efficacy in reducing mortality and the rate of reinfarction. A single daily 325-mg tablet is effective and produces side-effect incidences of only zero to two percent above those produced by placebo. This article assesses the current state of knowledge regarding the value of aspirin therapy in survivors of acute MI and the implications for clinical practice.
No takes yet. Share an insight, caveat, or question.
Rumore et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: